1. Managing Comorbidities in ADHD

2. Introduction

3. Common Comorbidities

4. Implications of Comorbidities

5. Common Challenges and Barriers in ADHD

6. Common Challenges and Barriers in ADHD (cont)

7. Common Challenges and Barriers in ADHD (cont)

8. Adverse Effects of Available Therapies

9. Where Are We Now With the Treatment of ADHD?

10. Dasotraline A DNRI With High Potency for DA Reuptake

11. Dasotraline Efficacy

12. Dasotraline AEs

13. Centanafadine An NDSRI, With Potency NE > DA > S Reuptake

14. Centanafadine Efficacy in the Phase 2a Study

15. Centanafadine Most Common TRAEs (≥ 10%)

16. Viloxazine An SNMA

17. Viloxazine Phase 3 Trials in Children

18. Viloxazine Summary of Results in Trials With Children

19. Viloxazine Phase 3 Trials in Adolescents

20. Viloxazine Efficacy Results From Study 302

21. Practical Advantages of Nonstimulant Medications for Patients With ADHD

22. Practical Insights for Using Nonstimulant Medications in Your Practice

23. Ongoing Challenges

24. Summary and Conclusions

25. Abbreviations

26. Abbreviations (cont)